Portal de Periódicos da CAPES

Real world evidence: Abiraterone use post-docetaxel in metastatic castrate-resistant prostate cancer

2018; SAGE Publishing; Volume: 25; Issue: 6 Linguagem: Inglês

10.1177/1078155218784716

1477-092X

Alisha Shivji, Raafi Ali, Scott North, Michael Sawyer, Sunita Ghosh, Carole Chambers,

Radiopharmaceutical Chemistry and Applications

The COU-AA-301 trial demonstrated that in men with metastatic castrate-resistant prostate cancer using abiraterone post-docetaxel increased overall survival. This study aims to assess this conclusion in a real world context.Retrospective chart review of a provincial Pharmacy BDM Database (a pharmacy dispensing software) and a provincial Electronic Chart (ARIA). Dispensing data, information on the state of the disease before and after abiraterone use, and information regarding effects of abiraterone were gathered.Cancer centers in Alberta, Canada.Metastatic castrate-resistant prostate cancer (CRPC) patients on abiraterone outside of a clinical trial who have previously had docetaxel chemotherapy for CRPC between February 2012 and May 2014.Overall survival from the time of abiraterone initiation.Overall survival increase of 17 months was consistent with the survival increase of 14.8 months observed in the pivotal trial.Abiraterone is a valuable therapy post-docetaxel for metastatic CRPC, as in a real world context it demonstrated an increase in overall survival that was consistent with the findings of the clinical trial despite including a patient population of older age and lower performance status.